Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and CAR-T cell therapy research.
Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA.
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
PARP14 is a novel target in STAT6 mutant follicular lymphoma
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models
Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine work‐up of tumours
Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma
Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2
Author Correction: Molecular subtypes of diffuse large B celllymphoma are associated with distinct pathogenic mechanisms and outcomes
A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
<i>TP53</i> mutation and survival in aggressive B cell lymphoma
Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma